Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ezetimibe (Primary) ; Simvastatin
Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II
Focus Therapeutic Use
Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough; Schering-Plough Research Institute

04 Nov 2009 Schering-Plough has been merged into Merck & Co under the name Merck & Co., according to Merck & Co media release.
21 Oct 2008 Primary endpoint 'Low density lipoprotein cholesterol level' has been met according to results published in the Journal of the American College of Cardiology .
21 Oct 2008 Results published in the Journal of the American College of Cardiology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com